In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the challenges facing abuse-deterrent opioids as their manufacturers attempt to bring them to market.
In this clip, Rabia Atayee, PharmD, of UC San Diego Skaggs School of Pharmacy discusses the opioid epidemic and what steps pharmacists and insurers can take to help address the opioid epidemic. She also addresses the role of abuse-deterrent formulations in combatting the opioid epidemic.
The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.
John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the digital innovations that will have major effects on the cardiovascular field in years to come. He discussed the topic at the European Society of Cardiology Meeting, 2017.